Like many businesses, pharmaceutical services provider Two Labs wanted to make a change to its office environment after the Covid-19 pandemic altered the way people work.
Envision Pharma Group (Envision) announced today the appointment of Bill Shirey as President of Life Science Commercialization. Overseeing the Two Labs and Riparian brands, Bill will focus on enhancing Envision’s commercialization and compliance solutions, delivering customized strategies that help bring pharmaceutical products to market and maintain compliance across the product life cycle through industry expertise, integration, and strategic implementation.
Pharmaceutical and medical device manufacturers launching their first product in the US face several complex challenges while preparing for the required collection and reporting of transfers of value provided to healthcare providers (HCPs) and healthcare organisations (HCOs). The many unique federal and state legal requirements, coupled with steep penalties for inaccurate, incomplete, or late reporting, underscore the critical need for a strategic, well-organised transparency reporting programme.
Today, Two Labs, an Envision Pharma Company and industry leader in pharma services, officially launched its Sunshine Transparency and Aggregate Spend service. This service offering is designed to help emerging pharmaceutical manufacturers streamline their aggregate spend activities, including reporting payments and transfers of value provided to healthcare professionals (HCPs) and healthcare organizations (HCOs).
With only a few months left until the final DSCSA compliance deadline, our Director of Serialization, Michael Rowe, shared his thoughts in an Outsourced Pharma article on what companies should be doing now to make sure they’re ready.
Two Labs celebrates a special milestone on July 1st – its 20th anniversary! In the two decades since its founding, the company has enjoyed significant growth in both size and services, and continues to drive innovation in the pursuit of improving the lives of others.
Two Labs is officially unveiling its State Drug Price Transparency (DPT) managed service offerings to help emerging pharmaceutical manufacturers navigate the evolving regulatory landscape imposed by each state's own independent reporting requirements. Read the press release.
REMS are FDA-mandated, post-marketing safety programs that can be required to appropriately balance a drug's benefits and risks to support safe use. These safety programs are most often required during the NDA or biologics license application (BLA) process to address risks identified in development.
"We've deepened our bench of experts by adding some of the most experienced REMS professionals to our team, including Melissa Landers," said Howard Miller, CEO of Two Labs.
Emerging manufacturers have a strength in how close to and how passionate they are about the science they are developing. But because they are hyper-focused on the groundbreaking science they're working on, it can be hard to come up from the weeds to put together the launch support that their product needs. And often, one of the most underestimated parts of that launch plan is medical communications.
